Logo

Ipsen Signs an Exclusive License Agreement with GENFIT for Elafibranor to Treat Primary Biliary Cholangitis

Share this

Ipsen Signs an Exclusive License Agreement with GENFIT for Elafibranor to Treat Primary Biliary Cholangitis

Shots:

  • GENFIT to receive ~$543.32M including $135.83M up front, $31.69M as equity investment, ~$407.50M in regulatory, commercial & sales-based milestone along with royalties of ~20%. Ipsen gets an exclusive license globally to develop, manufacture & commercialize elafibranor, currently in P-III (ELATIVE) trial for PBC
  • The agreement combines GENFIT’s expertise & technologies with Ipsen’s capabilities to develop elafibranor for PBC. The collaboration also provides an access to Ipsen for other clinical programs
  • GENFIT will be responsible for the P-III ELATIVE trial. Ipsen will lead an additional clinical development, including completion of the ELATIVE trial & global commercialization

Ref: Businesswire | Image: Ipsen 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions